Challenges in the Management of ADHD

Medical Case Views "Challenges in the Management of ADHD"
Jointly sponsored by the Duke University School of Medicine and Healthcare First

Release Date: April 30, 2007
Expiration Date: April 29, 2008
Estimated Time to complete: one (1) hour

This activity is supported by an educational grant from Shire Pharmaceuticals Inc.

Agenda

Introduction-Moderator
Patient Case #1 "Abuse & Diversion"
Panel Views/Discussion
Final Views- Panelists
Patient Case #2 "Compliance"
Panel Views/Discussion
Final Views- Panelists
Closing-Moderator

Panel

George Bright, MD
David W. Goodman, MD
Andrew A. Nierenberg, MD
Timothy E. Wilens, MD
Peter Salgo, MD-moderator

Statement of Need

Attention deficit hyperactivity disorder (ADHD) is the most prominently diagnosed and treated psychiatric disorder in children. Estimates are that approximately 5% of the population are affected with this disorder and is present in approximately 2 million children in the US. Historically, clinicians have believed that the occurrence of ADHD resolves after patients enter adulthood. Therefore, the diagnosis and treatment of ADHD in adults remains an issue of considerable concern. However, The National Co-morbidity Survey actually showed that 4.4% of the adult population (roughly 9 million adults) in the U.S. has ADHD and that only 2 million adults are treated on a monthly basis. Obviously, there is much work to do since 7 million adults in the US remain undiagnosed or untreated.

Despite the overwhelming evidence, the difficulty of diagnosing and treating patients with ADHD continues and the landscape is wrought with additional difficulties. In children, issues regarding parental perceptions, treatments and their side effect profiles, as well as the presence of comorbid conditions persist. In adults and adolescents, issues regarding treatments and comorbid conditions are also inherent. However, adolescents and adults are also plagued by issues of substance abuse and diversion, compliance, and social stigmas.

Effective management of ADHD can be greatly enhanced through the education of clinicians in a Medical Case Views activity format featuring expert faculty views on challenging cases involving symptom recognition, treatment selection, tolerability, and compliance to provide better patient care.

Learning Objectives

At the conclusion of this activity, participants should be able to:

Activity Medical Director
Scott H. Kollins, Ph.D.
Associate Professor
Director, Duke ADHD Program
Department of Psychiatry
Duke University Medical Center

Panel

George Bright, MD
Medical Director
Adolescent Health Center
Midlothian, VA

David W. Goodman, MD
Director
Adult Attention Deficit Disorder Center of Maryland;
Assistant Professor
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine;
Director
Suburban Psychiatric Associates, LLC
Baltimore, Maryland

Andrew A. Nierenberg, MD
Medical Director, Bipolar Clinic and Research Program
Associate Director, Depression Clinical and Research Program
Massachusetts General Hospital
Director NIMH Bipolar Trials Network
Associate Professor, Harvard Medical School

Timothy E. Wilens, MD
Associate Professor of Psychiatry
Harvard Medical School;
Director of Substance Abuse Program
Pediatric Psychopharmacology Research Unit
Massachusetts General Hospital
Boston, Massachusetts

Moderator
Peter L. Salgo, MD
National Television Medical Correspondent;
Clinical Professor of Medicine and Anesthesiology
Columbia University College of Physicians and Surgeons
New York, New York

Target Audience

This educational activity is designed for psychiatrists, primary-care physicians, and other health care professionals treating and managing ADHD in adults.

Credit Designation

The Duke University School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Duke University School of Medicine and Healthcare First. The Duke University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Disclosure Summary

The following speakers and/or planning committee members have indicated they have no relationship(s) with industry to disclose relative to the content of this CME activity: Peter Salgo, MD

George Bright, MD, receives honoraria as a PI for Cephelon and Rickets. He receives honoraria as a consultant for Forrest. He receives honoraria from Shire as a speaker and advisory board member.

David Goodman, MD, receives honoraria as a PI for Alza/Ortho-McNeil Pharmaceuticals, Cephalon, Johnson & Johnson, New River Pharmaceuticals and Shire US. He receives honoraria as a consultant for Alza/Ortho-McNeil Pharmaceuticals, Shire US. He receives honoraria as a speaker for Alza/Ortho-McNeil Pharmaceuticals, Forest Laboratories, GlaxoSmithKline, Novartis, Shire US, and Wyeth.

Scott Kollins, MD, receives grants as a PI for New River Pharmaceuticals, Pfizer, Psychogenics Inc., Shire US. He receives honoraria as a consultant for Abbott Laboratories, Athenagen Inc., Eli Lilly and Company, Shire US. He receives honoraria as an advisory board member for Cephalon, Shire US.

Andrew Nierenberg, MD, receives honoraria as a PI for Eli Lilly and Company, Janssen, Pfizer, Wyeth-Ayerst, Forest Laboratories, Cyberonics Inc., Bristol-Myers Squibb Company, GlaxoSmithKline. He receives honoraria as a speaker from Eli Lilly and Company, Janssen, Wyeth-Ayerst, Forest Laboratories, Cyberonics Inc., Bristol-Myers Squibb Company, GlaxoSmithKline.

Timothy Wilens, MD, receives honoraria as a PI for Abbott Laboratories, Alza/Ortho-McNeil Pharmaceuticals, Cephalon, Eli Lilly and Company, Glaxo-SKB, Janssen, NIDA, NIMH, NICMH, NeuroSearch, Novartis, Pfizer, Saegis Pharmaceuticals, Sanofi-Synthelabo, Shire US; . He receives honoraria as a consultant for Abbott Laboratories, Alza/Ortho-McNeil Pharmaceuticals, Cephalon, Eli Lilly and Company, Glaxo-SKB, Janssen, NeuroSearch, Novartis, Pfizer, Saegis Pharmaceuticals, Sanofi-Synthelabo, Shire US; He receives honoraria as a speaker Abbott Laboratories, Alza/Ortho-McNeil Pharmaceuticals, Cephalon, Eli Lilly and Company, Glaxo-SmithKline, Janssen, NeuroSearch, Novartis, Pfizer, Saegis Pharmaceuticals, Sanofi-Synthelabo, Shire US.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnosis and treatment options of a specific patient’s medical condition.

How to Receive Credit

To receive credit participates must review the materials on accreditation information, target audience, learning objectives, and disclosure information; complete the entire self-assessment and evaluation/claim form and mail form to: Duke Office of CME
3100 Tower Boulevard, Suite 1300
Durham, NC 27707

Questions about the Video:

Healthcare First
9 Davison Avenue
Jamesburg, NJ 08831
Telephone: 732.521.2213

Questions about CME Credit:

Duke Office of Continuing Medical Education
Telephone: 919.401.1200
Email: cme@mc.duke.edu

Unapproved Use Disclosure
Duke School of Medicine requires CME faculty (speakers) to disclose to the attendees: 1) when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and 2) any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Copyright 2007 Duke University School of Medicine